January 02, 2018 2:25 p.m.
Teva Announces Launch of an Authorized Generic of Estrace® Cream in the United States
JERUSALEM--(BUSINESS WIRE)--Jan. 2, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Estrace®1 Cream (estradiol vaginal cream, USP, 0.01%), in the U.S.
Estradiol vaginal cream, USP, 0.01%, is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. This launch is an important addition to Teva’s generic women’s health portfolio and our growing line of menopause treatments.
[...]
Estradiol Vaginal Cream 0.01% had annual sales of approximately $426 million in the U.S., according to IMS data as of August 2017.
ir.tevapharm.com/...3925&p=irol-newsArticle&ID=2324461